ReviewEuropean journal of drug metabolism and pharmacokinetics2026
From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies.
Review in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intentional cytochrome P450 (CYP) inhibition has been proposed as a pharmacoeconomic strategy capable of reducing oncology drug costs (33-90%) while maintaining clinical efficacy. While the pharmacokinetic effects of CYP inhibition have long been recognized in antiviral and transplant medicine, recent clinical applications in oncology and haematology-particularly in cost-constrained settings-highlight its broader translational potential. Synthetic (e.g. ketoconazole, itraconazole) and natural inhibitors (e.g. grapefruit juice, curcumin) provide feasible pharmacologic options adaptable to varied healthcare infrastructures. Applications may extend beyond oncology to infectious diseases, immunosuppressive therapies, and other specialities. Despite regulatory and safety challenges-including pharmacogenomic variability and special population risks-clear frameworks are urgently needed to distinguish beneficial from hazardous interactions. Broader multicentre trials and ethical policy integration are required to establish intentional CYP inhibition as a validated global model of therapeutic equity and healthcare innovation.
Indexed as
Identifiers
41318718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.